Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review their AVTO6 ...

Alvotech (ALVO) and Teva Pharmaceuticals (TEVA) announced that the FDA has accepted for review a Biologics License Application, or BLA, for ...

Try Now>> See today’s best-performing stocks on TipRanks >> Read More on TEVA: Teva Pharmaceutical Industries NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Axsome Therapeutics has resolved the patent infringement lawsuit that it filed against Teva Pharmaceutical Industries after the generics powerhouse sought FDA approval for a copycat to Axsome's ...

Teva Pharmaceutical Industries ( NYSE:TEVA ) Full Year 2024 Results Key Financial Results Revenue: US$16.5b (up 4.4... This pharma stock has made strong gains over the past 12 months thanks to its ...

Considering Teva’s extended-release version of Austedo won a key approval in 2023, ramped-up competition in 2025 is something the team at Evercore ISI had anticipated. Even so, this year’s fir ...

Teva Pharmaceutical Industries Ltd is a global leader in the pharmaceutical industry, specializing in the development, manufacture, and distribution of generic and specialty medicines, as well as ...

Axsome Therapeutics shares were up 14% in premarket trading after reaching a settlement with Teva Pharmaceuticals. Shares were trading around $120.01. The stock is up 8.3% over the last year.

Intercontinental Exchange and RELX are among the stocks that are now expensive. We sell different types of products and services to both investment professionals and individual investors. These ...

Teva Pharmaceutical Industries ( NYSE:TEVA ) Full Year 2024 Results Key Financial Results Revenue: US$16.5b (up 4.4... This pharma stock has made strong gains over the past 12 months thanks to its ...

Axsome grants Teva a license to sell generic Auvelity starting in 2038 or 2039, resolving all ongoing patent litigation. Axsome's Q4 and full-year 2024 Auvelity sales are expected at $92.6M and $ ...

MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Paris:MEDCL): ACCESS HERE THE FULL PRESS RELEASE David Heuzé Head of Corporate and Financial Communications, and ESG david.heuze@Medincell.com ...